Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB.
Frigault MJ, et al. Among authors: jordan jt.
Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738.
Blood. 2022.
PMID: 35167655
Free PMC article.
Clinical Trial.